{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-277008","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.953145+00:00","generated_at":"2026-06-22T09:33:55.764936+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BridgeBio Q3 operating expense down 26% vs Q1 2022; positive Phase 2 data for BBP-418 and infigratinib","bullets":["Q3 operating costs $129.5M, down 26.2% from Q1 2022; net loss $137.3M vs $155.9M prior year.","Cash, equivalents and marketable securities $558.3M, providing runway into 2024.","BBP-418 12-month Phase 2: αDG glycosylation +0.21 at day 90, >75% creatine kinase reduction, no SAEs.","Low-dose infigratinib Phase 2 Cohort 5 enrolled with no SAEs; AHV update in H1 2023, Phase 3 planned.","First patient dosed in Phase 1/2 of BBP-398 plus Amgen's Lumakras for KRAS G12C; FDA Fast Track granted."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-277008","json":"https://secwatch.observer/filing/0001193125-22-277008.json","markdown":"https://secwatch.observer/filing/0001193125-22-277008.md","text":"https://secwatch.observer/filing/0001193125-22-277008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000119312522277008/0001193125-22-277008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000119312522277008/d389928d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:33:55.764936+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b40ce2c2b4c1afddd6c001277a712bf9257c0f36","claim":"BridgeBio Pharma, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"BridgeBio Pharma, Inc. (the “Company”) reported recent business updates and its financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1743881/000119312522277008/0001193125-22-277008-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}